[Unified assessment of adverse events of multiple sclerosis disease modifying drugs]

One of the important components of effective treatment оf multiple sclerosis is adherence to therapy and long-term patient compliance, as well as timely detection and correction of adverse events. Using disease modifying drugs (DMD) in general medical practice is very different from that in clinical trials, in particular, there is no uniform approach to identify the adverse events of therapy. The authors developed a form of the Adverse events of DMD questionnaire, and checked its reliability and validity.